GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Gross Margin %

BioStem Technologies (BioStem Technologies) Gross Margin % : 91.47% (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. BioStem Technologies's Gross Profit for the three months ended in Sep. 2023 was $3.29 Mil. BioStem Technologies's Revenue for the three months ended in Sep. 2023 was $3.60 Mil. Therefore, BioStem Technologies's Gross Margin % for the quarter that ended in Sep. 2023 was 91.47%.


The historical rank and industry rank for BioStem Technologies's Gross Margin % or its related term are showing as below:

BSEM' s Gross Margin % Range Over the Past 10 Years
Min: 36.04   Med: 51.13   Max: 89.27
Current: 89.27


During the past 13 years, the highest Gross Margin % of BioStem Technologies was 89.27%. The lowest was 36.04%. And the median was 51.13%.

BSEM's Gross Margin % is ranked better than
84.81% of 744 companies
in the Biotechnology industry
Industry Median: 59.38 vs BSEM: 89.27

BioStem Technologies had a gross margin of 91.47% for the quarter that ended in Sep. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BioStem Technologies was 12.10% per year.


BioStem Technologies Gross Margin % Historical Data

The historical data trend for BioStem Technologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies Gross Margin % Chart

BioStem Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.81 49.85 49.64 66.02 87.17

BioStem Technologies Quarterly Data
Sep15 Dec15 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.07 79.23 84.24 82.47 91.47

Competitive Comparison of BioStem Technologies's Gross Margin %

For the Biotechnology subindustry, BioStem Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Gross Margin % falls into.



BioStem Technologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

BioStem Technologies's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=6 / 6.875
=(Revenue - Cost of Goods Sold) / Revenue
=(6.875 - 0.882) / 6.875
=87.17 %

BioStem Technologies's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=3.3 / 3.599
=(Revenue - Cost of Goods Sold) / Revenue
=(3.599 - 0.307) / 3.599
=91.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BioStem Technologies  (OTCPK:BSEM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioStem Technologies had a gross margin of 91.47% for the quarter that ended in Sep. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BioStem Technologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioStem Technologies (BioStem Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.